Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. / Storgaard, Heidi; Cold, Frederik; Gluud, Lise L; Lauritsen, Tina Vilsbøll; Knop, Filip K.

I: Diabetes, Obesity and Metabolism, Bind 19, Nr. 6, 06.2017, s. 906-908.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Storgaard, H, Cold, F, Gluud, LL, Lauritsen, TV & Knop, FK 2017, 'Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, bind 19, nr. 6, s. 906-908. https://doi.org/10.1111/dom.12885

APA

Storgaard, H., Cold, F., Gluud, L. L., Lauritsen, T. V., & Knop, F. K. (2017). Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 19(6), 906-908. https://doi.org/10.1111/dom.12885

Vancouver

Storgaard H, Cold F, Gluud LL, Lauritsen TV, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2017 jun.;19(6):906-908. https://doi.org/10.1111/dom.12885

Author

Storgaard, Heidi ; Cold, Frederik ; Gluud, Lise L ; Lauritsen, Tina Vilsbøll ; Knop, Filip K. / Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. I: Diabetes, Obesity and Metabolism. 2017 ; Bind 19, Nr. 6. s. 906-908.

Bibtex

@article{081101f1778f43c0ae37638f3e3c1ad9,

title = "Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes",

abstract = "Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.",

keywords = "Journal Article",

author = "Heidi Storgaard and Frederik Cold and Gluud, {Lise L} and Lauritsen, {Tina Vilsb{\o}ll} and Knop, {Filip K}",

note = "{\textcopyright} 2017 John Wiley & Sons Ltd.",

year = "2017",

month = jun,

doi = "10.1111/dom.12885",

language = "English",

volume = "19",

pages = "906--908",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "6",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

AU - Storgaard, Heidi

AU - Cold, Frederik

AU - Gluud, Lise L

AU - Lauritsen, Tina Vilsbøll

AU - Knop, Filip K

PY - 2017/6

Y1 - 2017/6

N2 - Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.

AB - Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.

KW - Journal Article

U2 - 10.1111/dom.12885

DO - 10.1111/dom.12885

M3 - Journal article

C2 - 28105738

VL - 19

SP - 906

EP - 908

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -

ID: 174430923

Institut for Klinisk Medicin